Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

Veure altres versions (1)

Dades bibliogràfiques
Autors principals:	Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K
Format:	Journal article
Publicat:	2001

Ítems similars

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
per: Croucher, P, et al.
Publicat: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
per: Croucher, P, et al.
Publicat: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
per: Croucher, P, et al.
Publicat: (2003)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
per: Croucher, P, et al.
Publicat: (2001)

Osteoprotegerin and the development of myeloma bone disease
per: Croucher, P, et al.
Publicat: (2004)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
per: Vanderkerken, K, et al.
Publicat: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
per: Croucher, P, et al.
Publicat: (2002)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
per: Shipman, C, et al.
Publicat: (2002)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
per: De Leenheer, E, et al.
Publicat: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
per: Shipman, C, et al.
Publicat: (2000)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
per: Shipman, C, et al.
Publicat: (2000)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
per: Shipman, C, et al.
Publicat: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
per: Croucher, P, et al.
Publicat: (2003)

Bisphosphonates--mechanisms of action in multiple myeloma.
per: Shipman, C, et al.
Publicat: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
per: Shipman, C, et al.
Publicat: (2001)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
per: Croucher, P, et al.
Publicat: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
per: De Leenheer, E, et al.
Publicat: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
per: Shipman, C, et al.
Publicat: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
per: Shipman, C, et al.
Publicat: (2003)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
per: Shipman, C, et al.
Publicat: (2000)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
per: Huan Liu, et al.
Publicat: (2022-06-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
per: Dongyeop Shin, et al.
Publicat: (2024-01-01)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
per: Anđelković Zlatibor, et al.
Publicat: (2004-01-01)

The role of osteoprotegerin in breast and prostate cancer
per: Holen, I, et al.
Publicat: (2002)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
per: Dongzheng Gai, et al.
Publicat: (2022-09-01)

Osteolytic lesions: Multiple myeloma or prostate cancer?
per: Akshitha Devaraj, MBBS, et al.
Publicat: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
per: Aiken Dao, et al.
Publicat: (2022-12-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
per: Dirk Hose, et al.
Publicat: (2024-12-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
per: Clive Henry Buckle, et al.
Publicat: (2012-01-01)

Role of osteoprotegerin (OPG) in cancer.
per: Holen, I, et al.
Publicat: (2006)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
per: Mueller, G, et al.
Publicat: (2004)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
per: Locklin, R, et al.
Publicat: (2005)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
per: Mueller, G, et al.
Publicat: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
per: Edwards, C, et al.
Publicat: (2007)

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
per: Dirk Hose, et al.
Publicat: (2025-01-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
per: Domingos Sousa, et al.
Publicat: (2020-11-01)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
per: Shipman, C, et al.
Publicat: (1998)

Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling
per: Huan Liu, et al.
Publicat: (2021-06-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
per: Lwin, S, et al.
Publicat: (2017)

Metastatic breast cancer with osteolytic skull lesions suspected to be multiple myeloma
per: Young Mo Kang, et al.
Publicat: (2017-12-01)